US 2010/0304392 A1 · HEPATITIS B VIRAL VARIANTS WITH REDUCED SUSCEPTIBILITY TO NUCLEOSIDE ANALOGS AND USES THEREOF

Abstract

The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.

Claims3

Dependent claims

A method for determining whether a hepatitis B virus (“test virus”) from a human patient would exhibit reduced sensitivity to a substituted acyclic nucleoside phosphide selected from adefovir and tenofovir, the method comprising:

screening a nucleic acid molecule from the test virus for adefovir- or tenofovir-resistant mutations, the nucleic acid molecule comprising a nucleic acid sequence that encodes a reverse transcriptase domain of a DNA polymerase, the mutations selected from a mutation of codon 84 from valine to methionine;
a mutation at codon 214 from valine to adenine;
and co-mutations at codon 181 from adenine to threonine and codon 236 from asparagine to threonine;
wherein the mutation indicates that the test virus would exhibit reduced sensitivity to the substituted acyclic nucleoside phosphate.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

12/791,621Filed 1 Jun 2010

Priority

AU PS 1710/0212 Apr 2002

Published

2 Dec 2010

Term ends

Not estimatedThe source records don’t support an estimate.

Classification9 codes

C12Q 1/6876
Involving nucleic acids: nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
A61P 31/12
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antivirals
C07K 14/005
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: from viruses
C12N 7/00
Viruses

Family

Application10/963,333Continuation · filed 12 Oct 2004

Application11/166,004Continuation · filed 24 Jun 2005

Application11/860,727Continuation · filed 25 Sep 2007

Application12/791,621Continuation

US 2006/0051743 A1Published application

US 2009/0081637 A1Published application

US 7,384,747 B2Related patent

US 7,745,130 B2Related patent

US 8,592,143 B2Related patent

US 2010/0304392 A1This patent

From the US filing history. Foreign family members aren’t listed.

Hepatitis b viral variants with reduced susceptibility to nucleoside analogs and uses thereof

Life of this patent

Hepatitis b viral variants with reduced susceptibility to nucleoside analogs and uses thereof

Life of this patent

Abstract

Claims3